Which laboratory tests are needed to diagnose type 1 diabetes?

Laboratory Tests for Diagnosing Type 1 Diabetes

To diagnose type 1 diabetes, you need to first establish hyperglycemia using glucose or HbA1c testing, then confirm the autoimmune etiology with islet autoantibody testing, primarily starting with GAD antibodies. 1

Initial Diagnosis of Diabetes (Any Type)

The diagnosis begins by demonstrating hyperglycemia using any of these criteria 2:

• Fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L) measured in venous plasma 2
• 2-hour postload glucose >200 mg/dL (>11.1 mmol/L) during an oral glucose tolerance test 2
• Random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with symptoms of hyperglycemia 2
• HbA1c ≥6.5%, which reflects long-term glucose concentrations 2

Confirmation requirement: Unless the patient presents with classic symptoms of hyperglycemia or hyperglycemic crisis AND random plasma glucose ≥200 mg/dL, you must confirm the diagnosis with either a repeat abnormal test on a different day or two different abnormal tests (glucose and HbA1c) on the same day 1

Distinguishing Type 1 from Other Forms of Diabetes

Islet Autoantibody Testing (Primary Classification Tool)

Glutamic acid decarboxylase (GAD) antibodies should be the first autoantibody measured 1. This is the most common autoantibody in adult-onset autoimmune diabetes 3.

If GAD is negative, follow with 1:

• Islet tyrosine phosphatase 2 (IA-2) antibodies
• Zinc transporter 8 (ZnT8) antibodies where available
• Insulin autoantibodies (IAA) in individuals not yet treated with insulin 1

Critical caveat: In patients diagnosed at <35 years of age without clinical features of type 2 or monogenic diabetes, a negative autoantibody result does not exclude type 1 diabetes, since 5-10% of people with type 1 diabetes are antibody-negative 1

Positive islet autoantibodies confirm type 1 diabetes by establishing an autoimmune etiology 4

C-Peptide Testing (For Classification in Unclear Cases)

C-peptide testing is indicated when 1:

• The patient is already on insulin treatment
• Autoantibodies are negative and classification is uncertain
• You need to distinguish between type 1 and type 2 diabetes in adults >35 years

Testing protocol 1:

• Use a random sample (with concurrent glucose) within 5 hours of eating—this can replace formal stimulation testing
• Do not test within 2 weeks of a hyperglycemic emergency
• If the patient is insulin-treated, C-peptide must be measured before insulin discontinuation

Interpretation 1:

• <200 pmol/L (<0.6 ng/mL): Suggests type 1 diabetes (severe insulin deficiency)
• 200-600 pmol/L (0.6-1.8 ng/mL): Indeterminate
• >600 pmol/L (>1.8 ng/mL): Suggests type 2 diabetes (preserved beta-cell function)

Very low levels (<80 pmol/L) do not need repeat testing 1

Algorithmic Approach for Adults with Suspected Type 1 Diabetes

1. Establish hyperglycemia using glucose or HbA1c criteria 2

2. Test islet autoantibodies starting with GAD 1

3. If autoantibody positive: Diagnosis is type 1 diabetes 1

4. If autoantibody negative 1:

   • Age <35 years with no features of type 2 or monogenic diabetes: Still diagnose as type 1 diabetes (antibody-negative type 1 occurs in 5-10%)
   • Age >35 years: Consider clinical features and C-peptide testing to distinguish from type 2 diabetes

5. Consider monogenic diabetes testing if features present: HbA1c <7.5% at diagnosis, one parent with diabetes, specific syndromic features, or high probability on prediction models 1

Common Pitfalls to Avoid

• Don't skip autoantibody testing in adults: The distinction between type 1 and type 2 diabetes is critical for therapy choice, prognosis, and screening for coexistent autoimmune diseases 4
• Don't test C-peptide too early after ketoacidosis: Wait at least 2 weeks, as acute illness suppresses C-peptide levels 1
• Don't assume negative antibodies exclude type 1 diabetes in young adults: Up to 10% are antibody-negative 1
• Don't measure IAA after starting insulin: Exogenous insulin induces antibodies that confound interpretation 1